| Q38419657 | A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. |
| Q40100873 | Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. |
| Q62609705 | Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. |
| Q46639635 | Development of New Strategies for Echinocandins: Progress in Translational Research. |
| Q37253669 | Does Weight Impact Anidulafungin Pharmacokinetics? |
| Q36924037 | Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. |
| Q38164666 | Dosing considerations for obese patients receiving cancer chemotherapeutic agents |
| Q38660761 | Dosing of antifungal agents in obese people. |
| Q35806375 | Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people |
| Q30395441 | Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People |
| Q38215670 | Identification and management of invasive mycoses in internal medicine: a road-map for physicians |
| Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
| Q47214944 | Impact of total body weight on 30-day mortality in patients with gram-negative bacteremia. |
| Q58033439 | In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos |
| Q27014780 | Micafungin: an evidence-based review of its place in therapy |
| Q36667084 | Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection |
| Q64898954 | Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. |
| Q91525647 | Pharmacokinetics of Micafungin in Critically Ill Patients |
| Q57746174 | Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins |
| Q38763496 | Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients |
| Q53822956 | Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q36299584 | Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study |
| Q28082570 | Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna! |
| Q40187269 | Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations |
| Q28822540 | The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism |
| Q50118613 | We can do better: a fresh look at echinocandin dosing. |
| Q36785939 | Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths |
Search more.